Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(8):1087–1094. doi: 10.1038/bjc.1997.512

Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases.

G H Borchert 1, D N Melegos 1, G Tomlinson 1, M Giai 1, R Roagna 1, R Ponzone 1, L Sgro 1, E P Diamandis 1
PMCID: PMC2228085  PMID: 9376271

Abstract

Using a highly sensitive immunofluorometric procedure, we measured the total prostate-specific antigen (PSA) concentration in 632 sera obtained from female blood donors and women with idiopathic hirsutism, breast cancer or benign breast diseases. A total of 50 sera with total PSA > 15 ng l(-1) were fractionated by high-performance liquid chromatography (HPLC) in order to resolve the two immunoreactive molecular forms, i.e. free PSA (approximately 30 kDa) and PSA bound to alpha1-antichymotrypsin (PSA-ACT, 100 kDa). We found that breast cancer patients have presurgical serum total PSA levels similar to those of blood donors. Total serum PSA concentration decreases with age in women with idiopathic hirsutism, in cancer patients and in patients with benign breast diseases. The major molecular form of PSA in the serum of all normal and hirsute women (n = 15) is PSA bound to the proteinase inhibitor alpha1-antichymotrypsin. The major molecular form in 44% of presurgical cancer patient sera is free PSA. A total of 58% of benign breast disease patients also have in their serum mainly free PSA. We conclude that about half the patients with breast cancer or benign breast diseases have free PSA as the major molecular form in their serum, whereas patients without breast pathologies (normal blood donors, idiopathic hirsutism) have PSA bound to alpha1-antichymotrypsin as the major molecular form. The ratio of PSA/PSA-ACT may have value as a simple biochemical test for diagnosis of breast pathologies including breast cancer.

Full text

PDF
1087

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cuny C., Pham L., Kramp W., Sharp T., Soriano T. F. Evaluation of a two-site immunoradiometric assay for measuring noncomplexed (free) prostate-specific antigen. Clin Chem. 1996 Aug;42(8 Pt 1):1243–1249. [PubMed] [Google Scholar]
  2. Diamandis E. P., Yu H., López-Otín C. Prostate specific antigen--a new constituent of breast cyst fluid. Breast Cancer Res Treat. 1996;38(3):259–264. doi: 10.1007/BF01806144. [DOI] [PubMed] [Google Scholar]
  3. Diamandis E. P., Yu H. New biological functions of prostate-specific antigen? J Clin Endocrinol Metab. 1995 May;80(5):1515–1517. doi: 10.1210/jcem.80.5.7538144. [DOI] [PubMed] [Google Scholar]
  4. Ferguson R. A., Yu H., Kalyvas M., Zammit S., Diamandis E. P. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem. 1996 May;42(5):675–684. [PubMed] [Google Scholar]
  5. Giai M., Yu H., Roagna R., Ponzone R., Katsaros D., Levesque M. A., Diamandis E. P. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer. 1995 Sep;72(3):728–731. doi: 10.1038/bjc.1995.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Leinonen J., Lövgren T., Vornanen T., Stenman U. H. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clin Chem. 1993 Oct;39(10):2098–2103. [PubMed] [Google Scholar]
  7. Levesque M., Hu H., D'Costa M., Diamandis E. P. Prostate-specific antigen expression by various tumors. J Clin Lab Anal. 1995;9(2):123–128. doi: 10.1002/jcla.1860090209. [DOI] [PubMed] [Google Scholar]
  8. Lilja H., Christensson A., Dahlén U., Matikainen M. T., Nilsson O., Pettersson K., Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991 Sep;37(9):1618–1625. [PubMed] [Google Scholar]
  9. Luderer A. A., Chen Y. T., Soriano T. F., Kramp W. J., Carlson G., Cuny C., Sharp T., Smith W., Petteway J., Brawer M. K. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 1995 Aug;46(2):187–194. doi: 10.1016/s0090-4295(99)80192-7. [DOI] [PubMed] [Google Scholar]
  10. McCormack R. T., Rittenhouse H. G., Finlay J. A., Sokoloff R. L., Wang T. J., Wolfert R. L., Lilja H., Oesterling J. E. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995 May;45(5):729–744. doi: 10.1016/s0090-4295(99)80076-4. [DOI] [PubMed] [Google Scholar]
  11. Melegos D. N., Diamandis E. P. Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. Clin Biochem. 1996 Jun;29(3):193–200. doi: 10.1016/0009-9120(96)00014-e. [DOI] [PubMed] [Google Scholar]
  12. Sauter E. R., Daly M., Linahan K., Ehya H., Engstrom P. F., Bonney G., Ross E. A., Yu H., Diamandis E. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967–970. [PubMed] [Google Scholar]
  13. Stenman U. H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991 Jan 1;51(1):222–226. [PubMed] [Google Scholar]
  14. Yu H., Diamandis E. P., Levesque M., Giai M., Roagna R., Ponzone R., Sismondi P., Monne M., Croce C. M. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996;40(2):171–178. doi: 10.1007/BF01806212. [DOI] [PubMed] [Google Scholar]
  15. Yu H., Diamandis E. P. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem. 1995 Feb;41(2):204–210. [PubMed] [Google Scholar]
  16. Yu H., Diamandis E. P., Sutherland D. J. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem. 1994 Apr;27(2):75–79. doi: 10.1016/0009-9120(94)90015-9. [DOI] [PubMed] [Google Scholar]
  17. Yu H., Diamandis E. P., Zarghami N., Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat. 1994;32(3):291–300. doi: 10.1007/BF00666006. [DOI] [PubMed] [Google Scholar]
  18. Zarghami N., Grass L., Diamandis E. P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997;75(4):579–588. doi: 10.1038/bjc.1997.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zhang W. M., Leinonen J., Kalkkinen N., Dowell B., Stenman U. H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem. 1995 Nov;41(11):1567–1573. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES